On Tuesday, Following Stocks were among the “Top 100 Gainers” of U.S. Stock Market: Quiksilver, (NYSE:ZQK), Theravance (NASDAQ:THRX), ZIOPHARM Oncology (NASDAQ:ZIOP), Sony (NYSE:SNE)
Quiksilver, Inc. (NYSE:ZQK) reported financial results for the fiscal 2015 first quarter ended January 31, 2015.
Net proceeds, as stated, were $341 million contrast with $395 million. Net proceeds were down 4%, or $14 million, on a constant currency ongoing category basis.
America’s net proceeds, as stated, were $148 million contrast with $175 million. America’s net proceeds were down 8%, or $13 million, on constant currency ongoing category basis.
EMEA net proceeds, as stated, were $126 million contrast with $149 million. EMEA net proceeds were down 3%, or $3 million, on constant currency ongoing category basis.
Quiksilver, Inc. (NYSE:ZQK) enhanced 3.66%, and closed at $1.70. The company holds the market capitalization of $285.78M. For the last twelve months, the stock was able to keep return on equity at -135.80%, while return on assets at –20.50%, in response to its return on investment at -28.20%. Its 20-day moving average decreased -13.68%, below 50-day moving average of -16.63%, below 200-day moving average of -30.86% from the latest market price of $1.70. The mean recommendation of analysts for this stock is 2.70. (where 1=Buy, 5=Sale).
Quiksilver, Inc. (ZQK) designs, develops, and distributes branded apparel, footwear, accessories, and related products mostly for men, women, and children. The corporation provides its products for a range of activities, counting casual and outdoor lifestyle associated with surfing, skateboarding, snowboarding, BMX and motocross, rally car, and other activities.
Theravance Inc (NASDAQ:THRX) rose 3.63%, and closed at $18.10. The stock has the beta value of 2.24, and its volatility for the week is 7.28%, while for the month it is 6.36%. The company has the market capitalization of $2.04M. The company holds the book value per share of -1.95, whereas cash per share is 2.06. Price to sale ratio is -251.36. Analysts mean recommendation for the stock is said to be 3.00 (where 1=Buy, 5=sale).
Theravance Inc (THRX) a royalty administration corporation is focused on developing respiratory products. It receives royalty proceeds RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI), and VI monotherapy through the Long-Acting Beta2 Agonist partnershipcontract and the planned alliance contract with Glaxo Group Limited (GSK).
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) declared financial results for the fourth quarter and full year ended December 31, 2014, and offered an update on the corporation’s recent activities. This partnership continues to expand the scope of ZIOPHARM’s synthetic immuno-oncology programs. In December 2014, ZIOPHARM and Intrexon declared the presentation of clinical and preclinical studies from these programs at the American Association for Cancer Research (AACR) 2014 Immunology and Immunotherapy Meeting in Orlando, Florida.
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) inclined 3.63 %, and closed at $13.71. The company has the market capitalization of $1.52 billion. The beta value of the stock is 1.79. On the other hand the stock’s volatility for the week is 4.78%, and for the month is 7.23%. The stock’s price to book ratio is $-41.55, however price to sale ratio is $-1123.14. Analyst’s mean recommendation regarding this stock is 2.30. (Where 1=Buy, 5=Sale).
ZIOPHARM Oncology Inc. (ZIOP) a biotechnology corporation focuses on acquiring, developing, and commercializing cancer therapies. The corporation is employing novel gene expression, and control and cells technologies to deliver cell-based therapies for the treatment of cancer.
Sony Corp (ADR) (NYSE:SNE), along with ImageWare Systems, Inc. (OTCQB: IWSY); Identiv (NASDAQ: INVE), StrikeForce Technologies, Inc. (OTCQB: SFORD) all talked about security solutions in SecuritySolutionsWatch.com Interviews.
Sony Corp (ADR) (NYSE:SNE) raised 3.60%, and closed at $26.75. The stock has price to sale ratio of 0.48, however, price to book ratio is 1.47. With recent incline, the year-to-date (YTD) performance reflected a 29.88% incline last year. During the past month the stock gained 0.56%, bringing three-month performance to 31.19% and six-month performance to 41.68%. The mean recommendation of analysts for this stock is 1.00 (where 1=Buy, 5=Sale).
Sony Corp (ADR) (SNE) designs, develops, manufactures, and sells electronic equipment, instruments, and devices for consumer, professional, and industrial markets worldwide. It offers LCD televisions; home audio, Blu-ray disc players and recorders, and memory-based audio devices; compact digital, home-use video, and interchangeable single-lens cameras; and personal computers.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
